Crinetics Treats First Patient in Phase 2/3 BALANCE-CAH Trial of Atumelnant

Crinetics Pharmaceuticals Inc. (NASDAQ: CRTX) announced the dosing of the first patient in its Phase 2/3 BALANCE-CAH trial evaluating atumelnant for congenital adrenal hyperplasia (CAH). The randomized, double-blind study aims to enroll up to 150 participants across multiple sites globally. Atumelnant, a novel mineralocorticoid receptor antagonist, is being assessed for its efficacy and safety compared to placebo. The trial's primary endpoint will measure changes in urinary steroid metabolites. Crinetics' shares rose 3% in pre-market trading following the announcement. The company plans to release interim data in Q4 2026.